RxDoctor Payments Data

Guillermo Lopez, MD

Internal Medicine · Miami, FLNPI 1518187590

Payments from drug & device makers

$3,203in general payments, 2019–2025

Across 173 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$437
  • Lilly USA, LLC$329
  • Pfizer$314
  • Boehringer Ingelheim$268
  • AstraZeneca$207
  • plus $437 from 10 others

What the payments were for

  • Food & beverage$3,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,203 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$56,354
Medicare patients
198
Services billed
426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$206,105
OzempicSemaglutide177$204,245
JardianceEmpagliflozin90$83,523
ProliaDenosumab41$71,339
JanuviaSitagliptin Phosphate45$68,422
XareltoRivaroxaban65$61,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$61,363
TradjentaLinagliptin47$37,362
MounjaroTirzepatide29$37,085
Breo ElliptaFluticasone/Vilanterol51$22,447
EntrestoSacubitril/Valsartan22$19,740
Tresiba Flextouch U-100Insulin Degludec31$19,226
FarxigaDapagliflozin Propanediol12$15,638
Repatha SyringeEvolocumab25$13,967
RestasisCyclosporine15$13,762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$314$206,105230 claims
Novo NordiskOzempic$1,211$204,245177 claims
Boehringer IngelheimJardiance, Tradjenta$268$120,885137 claims
GSKTrelegy Ellipta, Breo Ellipta$437$83,810130 claims
AmgenProlia$97$71,33941 claims
AbbVieRestasis, Linzess, Synthroid, Namzaric$94$44,342161 claims
Lilly USA, LLCMounjaro$329$37,08529 claims
AstraZenecaFarxiga, Symbicort$207$20,21827 claims
NovartisEntresto$19$19,74022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →